SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 61.12-2.3%Oct 30 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jayhawk969 who wrote (5207)12/22/2001 11:46:54 AM
From: scaram(o)uche   of 52153
 
Two large, successful companies that had weak near-term pipes, Amgen due to poor selection of targets and "invented here" syndrome, Immunex due to some bad luck. One simply can't use this merger as a yard stick for the leveraged, smaller companies.

The fact? While AMGN has come back 15% and IMNX is way off its recent highs, the companies have a combined market cap of $75 billion on the back of three products.

That's a 1000-bagger for many small cap biotechs.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News